PCLOF (PharmaCielo) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )


What is PharmaCielo 3-Month Share Buyback Ratio?

PharmaCielo PCLOF +17.45% 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. The stock has 5 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. PharmaCielo's current 3-Month Share Buyback Ratio was 0.00%.

PharmaCielo  (OTCPK:PCLOF) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

PharmaCielo 3-Month Share Buyback Ratio Related Terms

PCLOF vs ZTS, UTHR: 3-Month Share Buyback Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCielo 3-Month Share Buyback Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where PharmaCielo's 3-Month Share Buyback Ratio falls into.


PharmaCielo 3-Month Share Buyback Ratio Calculation

PharmaCielo's 3-Month Share Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Sep. 2025 ) - Shares Outstanding (EOP) (Dec. 2025 )) / Shares Outstanding (EOP) (Sep. 2025 )
=(187.984 - 187.984) / 187.984
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of 0.00 mean?
PharmaCielo (PCLOF) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for PharmaCielo and its competitors.
Is PharmaCielo's 3-Month Share Buyback Ratio too high?
PharmaCielo's current 3-Month Share Buyback Ratio is 0.00.
How does PharmaCielo's 3-Month Share Buyback Ratio compare to ZTS and UTHR?
PharmaCielo's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Month Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for PharmaCielo and its competitors. PharmaCielo's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.09, compared to a current price of $0.04 — trading 50% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCielo Business Description

Other Exchanges PCLO:Canada
Address 82 Richmond Street East, Suite 805, Toronto, ON, CAN, M5C 1P1
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.